Patient-based strategy for systemic treatment of metastatic renal cell carcinoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics 2009. CA Cancer J. Clin.59, 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med.353, 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163, 408–417 (2000).
   PubMed Web of Science ®Google Scholar
• Rini BI, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Oncology22, 388–396 (2008).
   PubMed Web of Science ®Google Scholar
• Djulbegovic B, Loughran TP, Hornung C et al. The quality of medical evidence in hematology–oncology. Am. J. Med.106, 198–205 (1999).
   PubMedGoogle Scholar
• Kirchner H, Heinzer H, Roigas J, Overkamp F. Differenzialtherapie beim metastasierenden Nierenzellkarzinom. Der Onkologe14, 191–197 (2008).
   Google Scholar
• Coppin C, Porszolt F, Autenrieth M et al. Immunotherapy for advanced renal cell cancer (Review). Cochrane Database Syst. Rev.CD001425 (2005).
   Google Scholar
• Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interferon α-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol.22, 1188–1194 (2004).
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-α and s.c. interleukin-2. Cancer Biother. Radiopharm.20, 410–416 (2005).
   PubMed Web of Science ®Google Scholar
• Bordin V, Giani L, Meregalli S et al. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol. Int.64, 3–8 (2000).
   PubMed Web of Science ®Google Scholar
• Escudier B, Chevreau C, Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J. Clin. Oncol.17, 2039–2043 (1999).
   PubMed Web of Science ®Google Scholar
• Gore ME. interferon-α (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): results of the randomised MRC/EORTC RE04 trial. J. Clin. Oncol.26, (2008) (Abstract 5039a).
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacuzimab plus interferon a-2a for treatment of metastastic renal cell carcinoma: survival and biomarker analysis. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer8, 579–591 (2008).
   PubMed Web of Science ®Google Scholar
• Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer2, 672–682 (2002).
   Google Scholar
• Wilhelm SM, Carter C, Tang L et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Eisen T, Szczyklik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol.25 (2007) (Abstract 5023a).
   PubMedGoogle Scholar
• Szczylik C, Demkow T, Staehler M et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol.25 (2007) (Abstract 5025a).
   Google Scholar
• Jonasch E, Corn P, Ashe RG et al. Randomized Phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J. Clin. Oncol.25 (2007) (Abstract 5104a).
   Google Scholar
• Knox JJ, Figlin RA, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCSS) expanded access trial in North America: safety and efficacy. J. Clin. Oncol.25 (2007) (Abstract 5011a).
   PubMedGoogle Scholar
• Beck J, Bajetta E, Escudier B et al. A large open-label, non-comparative, Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer Suppl.5, 4506 (2007).
   Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-α (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J. Clin. Oncol.25 (2007) (Abstract 5024).
   Google Scholar
• Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-a as first-line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.26 (2008) (Abstract 5024).
   PubMedGoogle Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. DOI: 10.1200/JCO.2009.23.9764 (2010) (Epub ahead of print).
   Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S et al. Final results of the Phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). 2009 ASCO Annual Meeting; May 29-June 2; Orlando, FL. J. Clin. Oncol.27(Suppl.) 15s (2009) (Abstract 5020a).
   Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a Phase III trial of bevacizumab plus interferon-α versus interferon-α monotherapy in metastatic renal cell carcinoma. 2009 ASCO Annual Meeting; May 29-June 2; Orlando, FL. J. Clin. Oncol.27(Suppl.) 15s (2009) (Abstract 5019a).
   Google Scholar
• Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA et al. interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20, 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol.23, 832–841 (2005).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer R, Escudier B, Oudard S et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-III study. J. Clin. Oncol.26, (2008) (Abstract LBA5026).
   Google Scholar
• Motzer R, Escudier B, Oudard S et al. Efficacy of everolimus in adavanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Escudier B, Ravaud A, Oudard S et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann. Oncol.19, 72O (2008).
   Google Scholar
• Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol.27(Suppl.), 15s (2009) (Abstract 5021a).
   Google Scholar
• Dutcher JP, Wilding G, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J. Clin. Oncol.26, 5127 (2008) (Abstract 5127).
   Google Scholar
• Hutson TE, Davis ID, Machiels JH et al. Biomarker analysis and final efficacy and safety results of a Phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J. Clin. Oncol.26, (2008) (Abstract 5046).
   Google Scholar
• Witteles RM, Telli ML, Fisher GA et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J. Clin. Oncol.26, (2008) (Abstract 9597).
   PubMedGoogle Scholar
• Clement P, Wolter P, Stefan C et al. Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. J. Clin. Oncol.26, (2008) (Abstract 16145).
   PubMedGoogle Scholar
• Wolter P, Stefan C, Decallonne B et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br. J. Cancer99, 448–454 (2008).
   PubMed Web of Science ®Google Scholar
• Billemont B, Rixe O, Meric JB et al. Renal safety of sunitinib treatment: a prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC). Ann. Oncol.19, E01a (2008).
   Google Scholar
• De Souza PL, Radulovic S, Beck J et al. Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α. J. Clin. Oncol.26, (2008) (Abstract 5116).
   PubMedGoogle Scholar
• Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann. Oncol.19, 1369–1370 (2008).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Szczylik C, Feingold J et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol.19, 1387–1392 (2008).
   PubMed Web of Science ®Google Scholar
• Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol.53, 917–930 (2008).
   PubMed Web of Science ®Google Scholar
• Wood L, Bukowski RM, Dreicer R et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy. J. Clin. Oncol.26, (2008) (Abstract 16067a).
   PubMedGoogle Scholar
• Bajetta E, Ravaud A, Bracarda S et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥ 65 years with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.26, (2008) (Abstract 5095).
   PubMedGoogle Scholar
• Porta C, Bracarda S, Beck J et al. Efficacy and safety of sorafenib in elderly pts: results from a large open-label, non-comparative Phase III study of sorafenib in European pts with advanced RCC (EU-ARCCS). Ann. Oncol.19 (2008) (Abstract 596P).
   PubMedGoogle Scholar
• Bukowski RM, Stadler WM, Figlin RA et al. Safety and efficacy of sorafenib in elderly patients (pts) ≥ 65 years: a subset analysis from the advanced renal cell carcinoma sorafenib (ARCSS) expanded access program in North America. J. Clin. Oncol.26 (2008) (Abstract 5045).
   Google Scholar
• Plantade A, Choueiri T, Escudier B et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinsase inhibitors. J. Clin. Oncol.25 (2007) (Abstract 5037).
   Google Scholar
• Gore Me, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J. Clin. Oncol.25 (2007) (Abstract 5010).
   Google Scholar
• Stadler WM, Figlin RA, Ernstoff MS et al. The advanced renal cell carcinoma sorafenib (ARCSS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J. Clin. Oncol.25 (2007) (Abstract 5036).
   Google Scholar
• Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol.26, 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Plimack ER, Jonasch E, Bekele BN et al. Sunitinib in non-clear cell renal carcinoma (ncc-RCC): a Phase II study. J. Clin. Oncol.26 (2008) (Abstract 5112).
   Google Scholar
• Strumberg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J. Clin. Oncol.26, 3469–3471 (2008).
   PubMed Web of Science ®Google Scholar
• Schouten LJ, Rutten J, Huveneers HA et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer94, 2698–2705 (2002).
   PubMed Web of Science ®Google Scholar
• Henderson CA, Bukowski RM, Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J. Clin. Oncol.25(18), (2007) (Abstract 15506).
   Google Scholar
• Hariharan S, Szczyklik C, Porta C et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (METS): data from an expanded access trial. J. Clin. Oncol.26 (2008) (Abstract 5094).
   Google Scholar
• Massard C, Zonierek J, Laplanche A et al. Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a Phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann. Oncol.17 (2006) (Abstract 454P).
   PubMedGoogle Scholar
• Helgason HH, Mallo HA, Droogendijk H et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J. Clin. Oncol.26, 152–154 (2008).
   PubMedGoogle Scholar
• Rini BI. Clinical prognostic and predictive markers for metastatic RCC therapeutic choices. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Rathmell WK, Stadler WM, Rini BI. Rational therapeutic choices and strategies for patients with metastatic renal cancer. Am. Soc. Clin. Oncol. Ed. Book192–198 (2008).
   Google Scholar
• Kirkali Z. Will we be able to ‘cure’ metastatic renal cell carcinoma like we cure testicular tumours? Eur. Urol.54, 712–714 (2008).
   PubMedGoogle Scholar
• Bellmunt J, Mulders P, Szczylik C et al. Defining a new patient-focused treatment approach to renal cell carcinoma (RCC). Ann. Oncol.19 (2008) (Abstract 612P).
   Google Scholar
• Gore M. What are the problems that are to be solved in the future? Presented at: ESMO Annual Meeting. Stockholm, Sweden, 12–16 September (2008).
   Google Scholar
• Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal carcinoma. J. Urol.182, 29–34 (2009).
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer115(1), 61–67 (2009).
   PubMed Web of Science ®Google Scholar
• Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol.54, 1373–1378 (2008).
   PubMed Web of Science ®Google Scholar
• Tamaskar A, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol.179, 81–86 (2008).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Brick AJ, McDermott S et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann. Oncol.19(Suppl. 8), (2008) (Abstract 593P).
   Google Scholar
• Porta C, Procopio G, Sabbatini R et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur. Urol. Suppl.8(4), 183(252) (2009).
   Google Scholar
• Vickers MM, Choueiri TK, Percy A et al. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): what next? J. Clin. Oncol.27(Suppl.), 15s (2009) (Abstract 5098a).
   Google Scholar
• Shepard DR, Rini BI, Garcia JA et al. A multicenter prospective trial of sorafenib in patients with metastatic clear cell carcinoma refractory to prior sunitinib and bevacizumab. J. Clin. Oncol.26 (2008) (Abstract 5123a).
   Google Scholar
• Van der Veeldt AAM, Boven E, Helgason HH et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br. J. Cancer99, 259–265 (2008).
   PubMedGoogle Scholar
• Melichar B, Koralewski P, Pluzanska A et al. First-line bevacizumab improves progression-free survival with lower doses of interferon a2a in the treatment of patients with metastastic renal cell carcinoma (AVOREN). Eur. J. Cancer Suppl.5, 304–304 (2007).
   Web of Science ®Google Scholar
• Dutcher J, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic-risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon a. J. Clin. Oncol.25 (2007) (Abstract 5033a).
   Google Scholar
• Richter S, Pfister D, Thüer D et al. Second line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie31 (2008) (Abstract V684a).
   PubMedGoogle Scholar
• Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.26 (2008) (Abstract 5100a).
   Google Scholar
• Fischer P, Patel P, Carducci MA et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J. Clin. Oncol.26, (2008) (Abstract 16020a).
   PubMedGoogle Scholar
• Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol.26 (2008) (Abstract 5010a).
   Google Scholar
• Rosenberg JE, Weinberg VK, Claros C et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J. Clin. Oncol.26 (2008) (Abstract 5109a).
   Google Scholar
• Giessinger S, Amato RJ, Jac J et al. A Phase I study with a daily regimen of the mTOR inhibitor RAD001 (everolimus) plus sorafenib for patients with metastatic renal cell cancer (mRCC). J. Clin. Oncol.26 (2008) (Abstract 14603a).
   Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol.26, 3709–3714 (2008).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Flaherty KT, Atkins MB et al. Final results of a Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer. J. Clin. Oncol.26 (2008) (Abstract 5011a).
   Google Scholar
• Merchan JR, Liu G, Fitch T et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J. Clin. Oncol.25 (2007) (Abstract 5034a).
   Google Scholar
• Brunello A, Sacco C, Barile C et al. Sunitinib in elderly patients (>=70 years) with metatsatic renal cell carcinoma (mRCC): multicenter analysis of tolerability and efficacy. Ann. Oncol.19 (2008) (Abstract 657P).
   Google Scholar
• Bokemeyer C, Porta C, Beck J et al. Efficacy and safety of sorafenib in pts with brain and bone metastases: Results from a large openlabel, non-comparative Phase III study of sorafenib in European pts with advanced rcc (EU-ARCCS). Ann. Oncol.19 (2008) (Abstract 595P).
   Google Scholar
• Eisen T, Beck J, Procopio G et al. Large open label, non-comparative Phase III study of sorafenib in European pts with advanced RCC (EU-ARCCS): subgroup analysis of pts with and without baseline clinical cardiovascular diseases (CCD). Ann. Oncol.19 (2008) (Abstract 602P).
   Google Scholar
• Tolcher A, Appleman L, Mita A et al. Effect of sorafenib treatment on left ventricular ejection fraction in cancer patients: an open-label, Phase I study. Ann. Oncol.19 (2008) (Abstract 552P).
   Google Scholar
• Snow H, Brueckner A, Gelder M et al. Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types. Ann. Oncol.19 (2008) (Abstract 553P).
   Google Scholar
• Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology76(5), 350–354 (2009).
   PubMed Web of Science ®Google Scholar
• Patnaik A, Ricart A, Cooper J et al. A Phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J. Clin. Oncol.25 (2007) (Abstract 3512a).
   PubMedGoogle Scholar